https://orcid.org/0009-0005-1011-7661
About the Authors
- Taner Karagöl
-
Contributed equally to this work with: Taner Karagöl, Alper Karagöl
Roles Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing
Affiliation Istanbul University Istanbul Medical Faculty, Istanbul, Turkey
- Alper Karagöl
-
Contributed equally to this work with: Taner Karagöl, Alper Karagöl
Roles Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing
Affiliation Istanbul University Istanbul Medical Faculty, Istanbul, Turkey
- Shuguang Zhang
-
Roles Conceptualization, Project administration, Supervision, Writing – review & editing
* E-mail: taner.karagol@gmail.com
Affiliation Laboratory of Molecular Architecture, Media Lab, Massachusetts Institute of Technology, Cambridge, MA, United States of America
Competing Interests
Massachusetts Institute of Technology (MIT) filed several patent applications for the QTY code for GPCRs and OH2Laboratories licensed the technology from MIT to work on water-soluble GPCR variants. However, this article does not study GPCRs. SZ is an inventor of the QTY code and has a minor equity of OH2Laboratories. S.Z. founded a startup 511 Therapeutics to generate therapeutic monoclonal antibodies against solute carrier transporters to treat pancreatic cancer. S.Z. has majority equity in 511 Therapeutics. 511 Therapeutics sponsored the study but had no influence and interference in the design of the study, in the data collection, analyses, or interpretation of data and in the writing of the manuscript, or in the decision to publish the results. All other authors have no competing interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.